|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081228 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-26 17:55:04 |
|
注册时间: Date of Registration: |
2024-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
全喉术后患者非同期行喉-气管-食管-甲状腺多器官簇联合移植:一项前瞻性、单中心、开放、单臂临床研究 |
|
Public title: |
Non-simultaneous combined laryngeal-tracheal-esophageal-thyroid multi-organ cluster transplantation in patients after total laryngectomy: a prospective, single-centre, open-label, single-arm clinical study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
全喉术后患者非同期行喉-气管-食管-甲状腺多器官簇联合移植:一项前瞻性、单中心、开放、单臂临床研究 |
|
Scientific title: |
Non-simultaneous combined laryngeal-tracheal-esophageal-thyroid multi-organ cluster transplantation in patients after total laryngectomy: a prospective, single-centre, open-label, single-arm clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
熊煜 |
研究负责人: |
陈飞 |
|
Applicant: |
Xiong Yu |
Study leader: |
Chen Fei |
|
申请注册联系人电话: Applicant telephone: |
+86 133 3241 3286 |
研究负责人电话: Study leader's telephone: |
+86 189 8060 2124 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
tracy_xiongyu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
hxchenfei@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号第一住院大楼耳鼻咽喉头颈外科 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号第一住院大楼耳鼻咽喉头颈外科 |
|
Applicant address: |
Department of Otolaryngology, Head and Neck surgery; West China Hospital, Sichuan University, Chengdu |
Study leader's address: |
Department of Otolaryngology, Head and Neck surgery; West China Hospital, Sichuan University, Chengdu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024年审(24)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Review Committee, West China Hospital, Sichuan University, China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-01 00:00:00 |
||
|
伦理委员会联系人: |
韩玉榕 |
||
|
Contact Name of the ethic committee: |
Han Yurong |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号四川大学华西医院老八教412-413室 |
||
|
Contact Address of the ethic committee: |
Room 412-413, Old Eight Teaching Building, West China Hospital, Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 3237 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
West China Hospital, Sichuan University, Chengdu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
新技术项目基金“喉气管移植”,资金卡号:20HXJS014 |
||||||||||||||||||||||
|
Source(s) of funding: |
New Technology Programme Fund "Laryngotracheal Transplantation", Funding Card No. 20HXJS014 |
||||||||||||||||||||||
|
Target disease: |
Laryngeal transplantation |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
在以全喉术后且无喉生存一定时间的患者为研究对象的前提下,探究喉-气管-食管-甲状腺多器官簇(可包含但不限于舌、下咽、食管、甲状旁腺)联合移植(以下简称为“喉气管移植”)的手术方式、围术期管理、功能康复及术后长期抗排异策略。从患者及其家属喉气管移植术前术后的心理测试结果、患者术前术后生活质量评估等结果对比此技术手段是否可改善患者及其家属的心理健康状态和生活质量;从基因组学、代谢组学、蛋白组学、呼吸道微生态、肠道微生态、体液及细胞免疫反应等多个维度出发,深入探究该手术对患者体内微环境的影响以及不同的基因及免疫状态对患者术后排异情况的影响,以期更精准地指导患者的围术期管理、术后长期抗排异策略以及术后长期随访计划的制定;从围术期肠内肠外营养支持、精准药物管理、预防颈部感染及其他并发症等精准护理角度出发,促进患者围手术期快速康复,早期进行功能锻炼,提高患者生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the surgical procedure, perioperative management, functional rehabilitation and long-term anti-rejection strategy of combined laryngeal-tracheal-esophageal-thyroid multi-organ cluster transplantation (including but not limited to tongue, hypopharynx, esophagus and parathyroid gland) based on the patients who survived without larynx for a certain time after total laryngectomy. The psychological test results of patients and their families before and after laryngotracheal transplantation, and the quality of life evaluation results of patients before and after surgery were compared to compare whether this technology can improve the mental health and quality of life of patients and their families. From multiple dimensions such as genomics, metabolomics, proteomics, respiratory microecology, intestinal microecology, humoral and cellular immune response, the effects of the surgery on the patient's internal microenvironment and the effects of different gene and immune status on the patient's postoperative rejection were explored, In order to more accurately guide the perioperative management of patients, postoperative long-term anti-rejection strategy and postoperative long-term follow-up plan formulation; From the perspective of precise nursing such as perioperative enteral and parenteral nutrition support, precise drug management, prevention of neck infection and other complications, we can promote the rapid recovery of patients during the perioperative period, perform early functional exercise, and improve the quality of life of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
入组患者需同时满足以下条件: (1)因各种病因(包括但不限于晚期喉癌、喉癌复发、下咽颈段食管癌、舌癌、创伤、晚期甲状腺癌术后复发等)导致全喉切除的患者; (2)年龄低于 75 岁,“无喉”生存时间达一年以上,对发声功能有迫切需求或为需高频用嗓的相关从业者; (3)全身基础情况良好或合并高血压、糖尿病、冠心病、甲状腺功能异常、肝肾功能异常等基础疾病经多科会诊评估后可行手术的患者; (4)愿意承担终生服用免疫抑制药物及所面临的风险或此前因其他病因(例如:已行其他器官移植术,某些风湿免疫类疾病等)已需终生服用免疫抑制药物的患者; |
||||||||||||||||||||||
|
Inclusion criteria |
Enrolled patients are required to fulfil the following conditions at the same time: (1) Patients who underwent total laryngectomy due to various causes (including but not limited to advanced laryngeal cancer, laryngeal cancer recurrence, hypopharyngeal and cervical esophageal cancer, tongue cancer, trauma, postoperative recurrence of advanced thyroid cancer, etc.); (2) Those who are under 75 years old, have lived "without laryngeal" for more than one year, and have an urgent need for voice function or are related practitioners who need to use throat frequently; (3) Patients with good general condition or combined with hypertension, diabetes, coronary heart disease, thyroid dysfunction, liver and kidney dysfunction and other basic diseases could be treated by surgery after multi-disciplinary consultation; (4) Willingness to take immunosuppressive drugs for life and the risks involved, or prior exposure to immunosuppressive drugs due to other causes (e.g.Other organ transplantation, some rheumatic diseases, etc.) patients who need life-long immunosuppressive drugs; |
||||||||||||||||||||||
|
排除标准: |
如果患者符合以下任一标准,则不入组: (1)年龄大于 75 岁,对发声功能等喉功能无迫切需求的患者; (2)全身情况较差,无法忍受喉气管移植手术及终生免疫抑制治疗的患者; (3)患者全喉切除术后目前处于带瘤生存状态(包括但不限于原位复发、远处转移、其他部位新发肿瘤); |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients were not enrolled if they met any of the following criteria: (1) Patients older than 75 years with no urgent need for laryngeal function such as voice function; (2) Patients with poor general condition who could not tolerate laryngotracheal transplantation and lifelong immunosuppressive therapy; (3) The patients were living with tumor after total laryngectomy (including but not limited to local recurrence, distant metastasis, and new tumors in other sites); |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-28 00:00:00至 To 2026-02-28 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-02-28 00:00:00 至 To 2026-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan, http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan, http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |